AG
FRTX

Advisor Group’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

Advisor Group’s Portfolio FRTX Stock Details FRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-3
Closed -$2K – 4935
2017
Q1 		$2K Buy
+3
New +$2.12K ﹤0.01% 4433

Other funds holding FRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Advisor Group's FRTX Position: Q2 2017 in Review

Advisor Group sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q2 2017, closing a stake of 3 shares — an estimated $2K sold.

Advisor Group first reported a position in FRTX in Q1 2017 and held it in 1 quarter. The position peaked at $2K in Q1 2017. 28 funds tracked by Wall St. Rank hold FRTX as of Q2 2017.

  • Advisor Group reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
  • Advisor Group sold 3 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q2 2017, an estimated $2K.
  • Advisor Group first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q1 2017 and held it in 1 quarter.
  • Advisor Group's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $2K in Q1 2017.
  • 28 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q2 2017.

Based on Advisor Group's 13F filing for Q2 2017, filed 11 Aug 2017.